Midazolam is a drug that can cause respiratory depression and lower doses are required for elderly patients. When combined with opiods, the risk of respiratory depression, coma and death is increased. Yet, this drug was recommended to be used in combination with Morphine for Covid-19 patients and DNS orders were given as part of triage protocols during the “pandemic”. Covid-19 treatment guidelines also specified that these drugs should not be witheld due to “inappropriate concern about respiratory depression”. Midazolam can paradoxically cause agitation and anxiety, yet is prescribed in greater dosages when these symptoms are observed instead of re-evaluating the appropriateness of the treatment.